Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fasudil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 8/20 | 0.98 |
| ▸ | ROCK1 known ✓ | Q13464 | 7/20 | 0.98 |
| ▸ | CCR2 | P41597 | 2/20 | 0.98 |
| ▸ | HTT | P42858 | 2/20 | 0.98 |
| ▸ | PRKCE | Q02156 | 6/20 | 0.95 |
| ▸ | PRKCD | Q05655 | 6/20 | 0.95 |
| ▸ | PRKD1 | Q15139 | 6/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.95 |
| ▸ | PRKD3 | O94806 | 5/20 | 0.95 |
| ▸ | PRKCG | P05129 | 5/20 | 0.95 |
| ▸ | PRKCB | P05771 | 5/20 | 0.95 |
| ▸ | PRKCA | P17252 | 5/20 | 0.95 |
| ▸ | PRKCH | P24723 | 5/20 | 0.95 |
| ▸ | PRKCI | P41743 | 5/20 | 0.95 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.95 |
| ▸ | PRKCZ | Q05513 | 5/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.95 |
| ▸ | PRKACA | P17612 | 4/20 | 0.95 |
| ▸ | PRKACG | P22612 | 4/20 | 0.95 |
| ▸ | PRKACB | P22694 | 4/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fasudil SCHEMBL6269513 | 1.00 | ROCK2 (0.98) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL2154690 | 1.00 | ROCK2 (0.98) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL30064396 | 1.00 | ROCK2 (0.98) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL4728659 | 1.00 | ROCK2 (0.98) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL30084458 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL6032335 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL29351490 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL29393852 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL599053 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL317082 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1CCR2HTTPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9012573-A | — | — | None | — | — | JP | disclosed |
| JP-9071582-A | — | — | None | — | — | JP | disclosed |
| CN-113968841-B | Preparation method of fasudil hydrochloride hemihydrate | 合肥久诺医药科技有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-113968841-A | Preparation method of fasudil hydrochloride hemihydrate | 合肥久诺医药科技有限公司 | 2022-01-25 | — | — | CN | disclosed |
| EP-1110553-B1 | SUSTAINED RELEASE ORAL PREPARATIONS OF FASUDIL HYDROCHLORIDE | ASAHI KASEI PHARMA CORP (JP) | 2013-03-27 | — | — | EP | disclosed |
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-20060280793-A1 | Oral sustained-release preparation of fasudil hydrochloride | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-12-14 | — | — | US | disclosed |
| US-7125567-B2 | Process for producing an oral sustained-release preparation of fasudil hydrochloride | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-10-24 | — | — | US | disclosed |
| EP-1550446-A1 | Use of 1-(5-isoquinolinesulfonyl) homopiperazine for treating and preventing hypopigmentary disorders | Switch Biotech Aktiengesellschaft (DE) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004096222-A1 | USE OF 1-(5-ISOQUINOLINESULFONYL)HOMOPIPERAZINE, ITS ACTIVE METABOLITES, ISOMERS AND SALTS FOR TREATING AND PREVENTING HYPOPIGMENTARY DISORDERS | SWITCH BIOTECH AG (DE) | 2004-11-11 | — | — | WO | disclosed |
| US-20040131679-A1 | Process for producing an oral sustained-release preparation of fasudil hydrochloride | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-07-08 | — | — | US | disclosed |
| US-6699508-B1 | SUSTAINED-RELEASE COATED PARTICLE COMPRISING A CORE COMPRISING DRUG AND A COATING COMPRISING INSOLUBLE AUXILIARY MATERIAL, THE PREPARATION EXHIBITING A SPECIFIC DISSOLUTION RATE | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-03-02 | — | — | US | disclosed |
| EP-1110553-A1 | SUSTAINED RELEASE ORAL PREPARATIONS OF FASUDIL HYDROCHLORIDE | Asahi Kasei Kabushiki Kaisha (JP) | 2001-06-27 | — | — | EP | disclosed |
| EP-0870767-B1 | 1-(5-ISOQUINOLINESULFONYL)HOMOPIPERAZINE HYDROCHLORIDE HYDRATES | ASAHI CHEMICAL IND (JP) | 2000-02-16 | — | — | EP | disclosed |
| US-5942505-A | GOOD DISSOLUTION AND SHAPEABILITY; TABLETS; VASODILATOR | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1999-08-24 | — | — | US | disclosed |
| EP-0870767-A1 | 1-(5-ISOQUINOLINESULFONYL)HOMOPIPERAZINE HYDROCHLORIDE HYDRATES | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1998-10-14 | — | — | EP | disclosed |
| JP-H0971582-A | 1-(5-ISOQUINOLINESULFONYL)HOMOPIPERAZINE HYDROCHLORIDE HEMIHYDRATE | ASAHI CHEM IND CO LTD | 1997-03-18 | — | — | JP | disclosed |
| JP-H0912573-A | 1-(5-ISOQUINOLINESULFONYL)HOMOPIPERAZINE HYDROCHLORIDE TRIHYRATE | ASAHI CHEM IND CO LTD | 1997-01-14 | — | — | JP | disclosed |
| JP-H00971582-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060280793-A1 | Oral sustained-release preparation of fasudil hydrochloride | MYLK, CFL1, CYP3A5 | ROCK2 74/4885ROCK1 20/4885CCR2 4467/4885 |
| US-20040131679-A1 | Process for producing an oral sustained-release preparation of fasudil hydrochloride | SAMM50, CYP3A5, VEGFA | ROCK2 125/4885ROCK1 41/4885CCR2 4398/4885 |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | ROCK2 2320/4885ROCK1 2248/4885CCR2 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.